Evaluation of Some Trace Elements in Follicular Fluid in ICSI Cases and Their Effect on ICSI Outcomes (ICSI)
December 5, 2024 updated by: Fatma Ahmed Saad Waley, Assiut University
Evaluation of Some Trace Elements in Follicular Fluid in Intracytoplasmic Sperm Injection(ICSI) Patients
To evaluate concentrations of some trace elements in the follicular fluid and their reproductive outcomes.
Study Overview
Status
Recruiting
Detailed Description
To evaluate some trace elements in the follicular fluid and their reproductive outcome
Study Type
Observational
Enrollment (Estimated)
154
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fatma Ahmed Waley
- Phone Number: 01064402617
- Email: www.fatma.waley@gmail.com
Study Contact Backup
- Name: Ahmed Mohammed Nasr
- Phone Number: 01012588888
- Email: anasr@edu.eg
Study Locations
-
-
-
Assiut, Egypt
- Recruiting
- Faculty of Medicine
-
Contact:
- Ahmed Mohammed Nasr, Prof
- Phone Number: 01012588888
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4
Description
Inclusion Criteria:good responders according to NICE guidelines with AMH more than 0.8ng/dl and antral follicular count more than 4 Exclusion Criteria:Poor responders according to ESHRE guidelines as advanced maternal age poor ovarian response and according to NICE guidelines AMH less than 0.8ng/dl
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
oocyte maturity
Time Frame: 2024 to 2026
|
Millimetres
|
2024 to 2026
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 24, 2024
Primary Completion (Estimated)
August 20, 2026
Study Completion (Estimated)
September 20, 2026
Study Registration Dates
First Submitted
October 18, 2024
First Submitted That Met QC Criteria
December 5, 2024
First Posted (Estimated)
December 6, 2024
Study Record Updates
Last Update Posted (Estimated)
December 6, 2024
Last Update Submitted That Met QC Criteria
December 5, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- AssiutU WHH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.